Tyra Biosciences, Inc.
NASDAQ:TYRA
16.42 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.502 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.126 | 0.122 | 0.102 | 0.082 | 0.086 | 0.083 | 0.082 | 0.082 | 0.069 | 0.064 | 0.05 | 0.041 | 0.027 | 0.022 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.126 | -0.122 | 0.4 | -0.082 | -0.086 | -0.083 | -0.082 | -0.082 | -0.069 | -0.064 | -0.05 | -0.041 | -0.027 | -0.022 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.797 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 17.871 | 17.081 | 20.575 | 19.271 | 12.162 | 10.408 | 10.4 | 10.915 | 12.047 | 9.645 | 7.25 | 5.484 | 4.381 | 3.522 | 2.928 | 1.862 | 1.42 | 0.993 |
| General & Administrative Expenses
| 5.535 | 5.119 | 4.957 | 4.692 | 3.852 | 3.926 | 4.618 | 2.73 | 3.381 | 5.189 | 2.682 | 1.154 | 1.127 | 0.689 | 0.749 | 0.47 | 0.412 | 0.463 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.535 | 5.119 | 4.957 | 4.692 | 3.852 | 3.926 | 4.618 | 2.73 | 3.381 | 5.189 | 2.682 | 1.154 | 1.127 | 0.689 | 0.749 | 0.47 | 0.412 | 0.463 |
| Other Expenses
| 0 | 0 | -0.011 | -0.005 | -0.021 | -0.001 | -0.033 | 0.005 | -0.013 | -0.01 | -0.003 | -0.007 | -0.008 | 0 | -0.006 | -0.007 | 0 | 0 |
| Operating Expenses
| 23.406 | 22.2 | 25.532 | 23.963 | 16.014 | 14.334 | 15.018 | 13.645 | 15.428 | 14.834 | 9.932 | 6.638 | 5.508 | 4.211 | 3.677 | 2.332 | 1.839 | 1.474 |
| Operating Income
| -23.532 | -22.322 | -25.634 | -23.963 | -16.014 | -14.334 | -15.018 | -13.645 | -15.428 | -14.834 | -9.932 | -6.638 | -5.508 | -4.211 | -3.677 | -2.332 | -1.832 | -1.456 |
| Operating Income Ratio
| 0 | 0 | -51.064 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.83 | 4.13 | 2.804 | -0.005 | -0.021 | 2.454 | 2.123 | 1.136 | 0.333 | 0.008 | -0.003 | -0.007 | -0.008 | 0.002 | -0.006 | -0.007 | -0.006 | -0.018 |
| Income Before Tax
| -18.702 | -18.192 | -22.83 | -21.152 | -13.272 | -11.88 | -12.895 | -12.509 | -15.095 | -14.826 | -9.93 | -6.643 | -5.512 | -4.209 | -3.685 | -2.339 | -1.838 | -1.474 |
| Income Before Tax Ratio
| 0 | 0 | -45.478 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.079 | 8.033 | -2.816 | -2.763 | -2.454 | -32.387 | -1.136 | -0.333 | -0.008 | -0.055 | -0.002 | -0.004 | 0 | -0.036 | 0 | 0 | 0 |
| Net Income
| -18.702 | -18.192 | -22.83 | -21.152 | -13.272 | -9.426 | 19.492 | -11.373 | -14.762 | -14.818 | -9.93 | -6.643 | -5.512 | -4.209 | -3.685 | -2.339 | -1.838 | -1.474 |
| Net Income Ratio
| 0 | 0 | -45.478 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.32 | -0.35 | -0.53 | -0.49 | -0.31 | -0.22 | 0.46 | -0.27 | -0.35 | -0.36 | -0.24 | -0.72 | -0.15 | -0.19 | -0.16 | -0.1 | -1.27 | -1.07 |
| EPS Diluted
| -0.32 | -0.35 | -0.53 | -0.49 | -0.31 | -0.22 | 0.46 | -0.27 | -0.35 | -0.36 | -0.24 | -0.72 | -0.15 | -0.19 | -0.16 | -0.1 | -1.27 | -1.07 |
| EBITDA
| -23.406 | -22.2 | -25.532 | -23.881 | -15.928 | -14.334 | -15.018 | -13.563 | -15.36 | -14.77 | -9.932 | -6.597 | -5.481 | -4.189 | -3.696 | -2.316 | -1.824 | -1.452 |
| EBITDA Ratio
| 0 | 0 | -50.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |